- Home
- IVA
as of 10-30-2026 3:39pm EST
Inventiva SA is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with unmet medical needs.
| Founded: | 2011 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 737.1M | IPO Year: | 2020 |
| Target Price: | $15.20 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $2.82 - $7.29 | Next Earning Date: | 09-28-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | -24.09% | Revenue Growth (next year): | -56.38% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Compare IVA vs Leading Stocks
See how IVA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IVA Inventiva S.A. American Depository Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.